Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. Atomoxetine is a selective norepinephrine re-uptake inhibitor. It appears to work by blocking or slowing the reabsorption of norepinephrine...
Strattera (atomoxetine hcl) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 and older, teens, and adults. Strattera should be used as part of a total treatment program for ADHD that may include counseling or other therapies...
Despite an expansion in health care provision, a new study has found that the growth of health care expenditure in the US has slowed down over the past decade.
Researchers from Georgia Tech have created a wearable computer glove that they say can teach people to read and write braille, even when their attention is elsewhere.
A 5-year study of capuchin monkeys suggests foraging for hard-to-find insects may have helped our early ancestors' brains evolve the thinking ability that led to advanced tool use.